Literature DB >> 18293376

Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung.

Antonio Marchetti1, Lara Felicioni, Giuseppe Pelosi, Maela Del Grammastro, Caterina Fumagalli, Mariagrazia Sciarrotta, Sara Malatesta, Antonio Chella, Fabio Barassi, Felice Mucilli, Pierpaolo Camplese, Tommaso D'Antuono, Rocco Sacco, Fiamma Buttitta.   

Abstract

The neurotrophic tyrosine receptor kinase (NTRK) family is potentially implicated in tumorigenesis and progression of several neoplastic diseases, including lung cancer. We investigated a large number of pulmonary neuroendocrine tumors (PNETs) and non-small cell lung carcinomas (NSCLCs) without morphological evidence of neuroendocrine differentiation for mutations in the NTRK gene family. A total of 538 primary lung carcinomas, including 17 typical carcinoids (TCs), 10 atypical carcinoids (ACs), 39 small cell lung carcinomas (SCLCs), 29 large cell neuroendocrine carcinomas (LCNECs), and 443 NSCLCs were evaluated by single-strand conformation polymorphism (SSCP) and sequencing of the tyrosine kinase domain (TKD) of NTRK1, NTRK2, and NTRK3. The NTRK1 gene was never found to be mutated. A total of 10 somatic mutations were detected in NTRK2 and NTRK3, mostly located in the activating and catalytic loops. NTRK mutations were seen in 9 (10%) out of 95 PNETs but in 0 out of 443 NSCLCs investigated. No mutations were observed in TCs, ACs, and SCLCs. Interestingly, all the mutations were restricted to the LCNEC histotype, in which they accounted for 31% of cases. A mutational analysis, performed after microdissection of LCNECs combined with adenocarcinoma (ADC), showed that only neuroendocrine areas were positive, suggesting that NTRK mutations are involved in the genesis of the neuroendocrine component of combined LCNECs. Our data indicate that somatic mutations in the TKD of NTRK genes are frequent in LCNECs. Such mutational events could represent an important step in the cancerogenesis of these tumors and may have potential implications for the selection of patients for targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18293376     DOI: 10.1002/humu.20707

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  26 in total

Review 1.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

2.  Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.

Authors:  Natasha Rekhtman; Maria C Pietanza; Matthew D Hellmann; Jarushka Naidoo; Arshi Arora; Helen Won; Darragh F Halpenny; Hangjun Wang; Shaozhou K Tian; Anya M Litvak; Paul K Paik; Alexander E Drilon; Nicholas Socci; John T Poirier; Ronglai Shen; Michael F Berger; Andre L Moreira; William D Travis; Charles M Rudin; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2016-03-09       Impact factor: 12.531

3.  Role and relevance of TrkB mutations and expression in non-small cell lung cancer.

Authors:  Taishi Harada; Yasushi Yatabe; Masafumi Takeshita; Takaomi Koga; Tokujiro Yano; Yisong Wang; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-01-17       Impact factor: 12.531

Review 4.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

Review 5.  TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Authors:  Shivaani Kummar; Ulrik N Lassen
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

6.  Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.

Authors:  Tsutomu Tatematsu; Hidefumi Sasaki; Shigeki Shimizu; Katsuhiro Okuda; Masayuki Shitara; Yu Hikosaka; Satoru Moriyama; Motoki Yano; Jeffrey Brown; Yoshitaka Fujii
Journal:  Mol Clin Oncol       Date:  2014-06-19

7.  Somatic mutations affect key pathways in lung adenocarcinoma.

Authors:  Li Ding; Gad Getz; David A Wheeler; Elaine R Mardis; Michael D McLellan; Kristian Cibulskis; Carrie Sougnez; Heidi Greulich; Donna M Muzny; Margaret B Morgan; Lucinda Fulton; Robert S Fulton; Qunyuan Zhang; Michael C Wendl; Michael S Lawrence; David E Larson; Ken Chen; David J Dooling; Aniko Sabo; Alicia C Hawes; Hua Shen; Shalini N Jhangiani; Lora R Lewis; Otis Hall; Yiming Zhu; Tittu Mathew; Yanru Ren; Jiqiang Yao; Steven E Scherer; Kerstin Clerc; Ginger A Metcalf; Brian Ng; Aleksandar Milosavljevic; Manuel L Gonzalez-Garay; John R Osborne; Rick Meyer; Xiaoqi Shi; Yuzhu Tang; Daniel C Koboldt; Ling Lin; Rachel Abbott; Tracie L Miner; Craig Pohl; Ginger Fewell; Carrie Haipek; Heather Schmidt; Brian H Dunford-Shore; Aldi Kraja; Seth D Crosby; Christopher S Sawyer; Tammi Vickery; Sacha Sander; Jody Robinson; Wendy Winckler; Jennifer Baldwin; Lucian R Chirieac; Amit Dutt; Tim Fennell; Megan Hanna; Bruce E Johnson; Robert C Onofrio; Roman K Thomas; Giovanni Tonon; Barbara A Weir; Xiaojun Zhao; Liuda Ziaugra; Michael C Zody; Thomas Giordano; Mark B Orringer; Jack A Roth; Margaret R Spitz; Ignacio I Wistuba; Bradley Ozenberger; Peter J Good; Andrew C Chang; David G Beer; Mark A Watson; Marc Ladanyi; Stephen Broderick; Akihiko Yoshizawa; William D Travis; William Pao; Michael A Province; George M Weinstock; Harold E Varmus; Stacey B Gabriel; Eric S Lander; Richard A Gibbs; Matthew Meyerson; Richard K Wilson
Journal:  Nature       Date:  2008-10-23       Impact factor: 49.962

8.  Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.

Authors:  Frank Hilberg; Ulrike Tontsch-Grunt; Anke Baum; Anh T Le; Robert C Doebele; Simone Lieb; Davide Gianni; Tilman Voss; Pilar Garin-Chesa; Christian Haslinger; Norbert Kraut
Journal:  J Pharmacol Exp Ther       Date:  2017-12-20       Impact factor: 4.030

Review 9.  NTRK fusion-positive cancers and TRK inhibitor therapy.

Authors:  Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

10.  c.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients.

Authors:  Beata S Lipska; Elzbieta Drozynska; Paola Scaruffi; Gian Paolo Tonini; Ewa Izycka-Swieszewska; Szymon Zietkiewicz; Anna Balcerska; Danuta Perek; Alicja Chybicka; Wojciech Biernat; Janusz Limon
Journal:  BMC Cancer       Date:  2009-12-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.